Thursday, June 5, 2025
VISIT ROYALMOK
Agarwood Times
  • Home
  • Agarwood
  • Health
  • Diseases
  • Diet & Fitness
  • Nutrition
  • Sleep Info
  • Meditation
  • Shop
No Result
View All Result
  • Home
  • Agarwood
  • Health
  • Diseases
  • Diet & Fitness
  • Nutrition
  • Sleep Info
  • Meditation
  • Shop
No Result
View All Result
Agarwood Times
No Result
View All Result

Leqembi and the risk of brain bleed in patients with Down syndrome

August 21, 2024
in Health
Reading Time: 4 mins read
0 0
A A
0
Home Health
Share on FacebookShare on Twitter


A yr in the past, after a lot fanfare and controversy, the Meals and Drug Administration permitted Eisai and Biogen’s lecanemab, an anti-amyloid drug that reasonably slowed cognitive decline in sufferers with Alzheimer’s illness. However the drug and its pharmacological cousin, Eli Lilly’s donanemab, have but to be prescribed for individuals with Down syndrome, the inhabitants with the best prevalence of the illness.

The remedy delay could be useful, nonetheless. When researchers handled autopsy mind tissue of individuals with Down syndrome with lecanemab, they decided that this inhabitants would possibly face larger threat elements. In comparison with the final inhabitants, their cerebral vasculature may put them at a better threat of mind hemorrhages and mind swelling — the identical unwanted side effects the FDA mentioned when it permitted the drug.

Continuing with warning is essential right here, stated Lei Liu, the examine’s lead creator and a neurologist at Brigham and Ladies’s Hospital.

“We clearly perceive that there’s a correlation with mind blood vessels and amyloid deposits with unwanted side effects of all these medication. We began to fret that if we give the Down syndrome affected person any such drugs, they are going to have stronger unwanted side effects,” stated Liu. “We wished to analyze if this drug will bind to the blood vessels.”

Though researchers like Liu perceive that threat theoretically, there’s scant knowledge on it as a result of individuals with Down Syndrome are traditionally excluded from medical trials. The info generated by the brand new examine, and different future research, may ultimately assist make life-extending Alzheimer’s medication like lecanemab obtainable to this inhabitants group that faces a 90% lifetime threat of growing the neurodegenerative illness.

Eisai, Biogen make case for long-term use of Alzheimer’s drug Leqembi with new knowledge

Over 18,000 individuals have participated in drug trials for these anti-amyloid antibodies, in keeping with analysis from LuMind IDSC, a gaggle that advocates for higher Down syndrome analysis. Not a single participant had Down syndrome. Most individuals with Down syndrome have an additional copy of the twenty first chromosome, which comprises the gene that codes for the amyloid precursor protein. From delivery, their genes make extra of the protein that’s the hallmark of Alzheimer’s illness.

LuMind IDSC president Hampus Hillerstrom says this analysis disparity should change. Alzheimer’s is so prevalent within the Down syndrome neighborhood {that a} 2023 RAND examine discovered that these therapies may ultimately enhance a person’s common lifespan with out the illness by 5 years. Caregiving for individuals over 45 years outdated with Down syndrome additionally prices $1 billion yearly. However Hillerstrom doesn’t need the potential advantages to return on the expense of individuals’s lives.

“This type of discovering must be considered while you’re planning a examine…of future medical trials in [people with] Down syndrome,” stated Lon Schneider, who directs the USC California Alzheimer’s Illness Heart and was unaffiliated with the examine. “It may additionally be a little bit of a warning.”

The examine, revealed in JAMA, analyzed postmortem mind tissue from 15 people with Down syndrome aged 43 to 68 years with Alzheimer’s illness. When researchers injected lecanemab into the tissue, the antibody readily sure with the amyloid deposits. That is what the drug is designed to do, prohibit these amyloid plaque deposits from forming.

Nevertheless, individuals with Down syndrome have larger ranges of cerebral amyloid angiopathy (CAA) — which means, their mind’s blood vessels naturally swell up with this protein. These protein deposits weaken vessel partitions, leaving them susceptible to leakage, i.e., a hemorrhage. Mind hemorrhages are unusual with Alzheimer’s illness, however research of lecanemab within the basic inhabitants discovered larger associations between the presence of CAAs and hemorrhages. Severe problems happen in lower than 1% of sufferers, despite the fact that there have been just a few, probably associated, deaths. So Liu hopes researchers proceed with warning when treating and dosing individuals with Down syndrome.

Consultants say that it’s nonetheless an open query how Alzheimer’s manifests in individuals with Down syndrome in comparison with the final inhabitants. The researchers didn’t take a look at how tissue from individuals with out Down syndrome or with out Alzheimer’s illness fared.

However the scientific neighborhood won’t have to attend lengthy to see the consequences of those medication on actual individuals as an alternative of tissue cultures. The primary trial of donanemab in individuals with Down syndrome is slated to start in 2025, in keeping with one in all its principal investigators, Michael Rafii, a neurologist at College of Southern California. He stated that they’re conscious of the elevated threat elements seen in Liu’s examine and plan to proceed with warning.

“This can be a critically essential examine and additional confirms that security trials of the amyloid-lowering antibodies have to be carried out in individuals with [Down syndrome] earlier than they’re prescribed within the clinic,” stated Rafii.



Source link

Tags: bleedBrainLeqembiPatientsRisksyndrome
Previous Post

Chocolate Zucchini Muffin Recipe

Next Post

Salcit partners with Google on AI technology to detect disease based on coughs

Related Posts

Lucet to Acquire Home Care Company Emcara Health
Health

Lucet to Acquire Home Care Company Emcara Health

June 5, 2025
Diabetes drug shows benefits for patients with liver disease
Health

Diabetes drug shows benefits for patients with liver disease

June 4, 2025
Household environments may affect the likelihood of children developing eczema
Health

Household environments may affect the likelihood of children developing eczema

June 4, 2025
UnitedHealth accidentally emails internal talking points to reporter
Health

UnitedHealth accidentally emails internal talking points to reporter

June 5, 2025
Scripta Insights, RxSaveCard partner for lower prescription drug costs
Health

Scripta Insights, RxSaveCard partner for lower prescription drug costs

June 5, 2025
Trump’s Cognitive ‘Decline’ Suggests He ‘Might Not Make It Through Four Years,’ Republican Strategist Says
Health

Trump’s Cognitive ‘Decline’ Suggests He ‘Might Not Make It Through Four Years,’ Republican Strategist Says

June 4, 2025
Next Post
Salcit partners with Google on AI technology to detect disease based on coughs

Salcit partners with Google on AI technology to detect disease based on coughs

US announces more support for Africa’s mpox response

US announces more support for Africa's mpox response

How Yoga and Stretching Aid in Recovery

How Yoga and Stretching Aid in Recovery

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

RECOMMENDED

Exercise Motivation May Rely On Gut Health, Study Finds
Diet & Fitness

Exercise Motivation May Rely On Gut Health, Study Finds

by admin
June 4, 2025
0

Printed in Nature, the research investigated which inner elements—if any—affect our need to train. The researchers analyzed a variety of...

Prior COVID vaccination produces immune response against new SARS-CoV-2 strains, study finds

Prior COVID vaccination produces immune response against new SARS-CoV-2 strains, study finds

May 29, 2025
Guidance requiring hospitals to provide emergency abortions revoked

Guidance requiring hospitals to provide emergency abortions revoked

June 4, 2025
Coreline Soft scores imaging AI supply contracts with UK NHS, Boehringer Ingelheim and more briefs

Coreline Soft scores imaging AI supply contracts with UK NHS, Boehringer Ingelheim and more briefs

May 30, 2025
Lecture 04 – Environment PT365 (Value Added) | #currentaffairs #upsc2025 #upscprelims #xias

Lecture 04 – Environment PT365 (Value Added) | #currentaffairs #upsc2025 #upscprelims #xias

June 2, 2025
4 Notable Health Tech Funding Announcements in May

4 Notable Health Tech Funding Announcements in May

June 1, 2025
Facebook Twitter Instagram Youtube RSS
Agarwood Times

Stay informed with the latest news, articles, and insights on agarwood cultivation, history, sustainability, and more. Explore the timeless allure of agarwood and deepen your understanding of this extraordinary natural resource.

CATEGORIES

  • Agarwood
  • Diet & Fitness
  • Diseases
  • Health
  • Meditation
  • Nutrition
  • Sleep Info
  • Uncategorized
No Result
View All Result

SITEMAP

  • About us
  • Advertise With Us
  • Disclaimer
  • Privacy Policy
  • DMCA
  • Cookie Privacy Policy
  • Terms and Conditions
  • Contact us

Copyright © 2024 Agarwood Times.
Agarwood Times is not responsible for the content of external sites.

No Result
View All Result
  • Home
  • Agarwood
  • Health
  • Diseases
  • Diet & Fitness
  • Nutrition
  • Sleep Info
  • Meditation
  • Shop
VISIT ROYALMOK

Copyright © 2024 Agarwood Times.
Agarwood Times is not responsible for the content of external sites.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In